7 December 2017
Vedanta Biosciences announces initiation of Phase 1a/1b trial for new drug class of rationally-defined bacteria consortia derived from the human microbiome
VE303 is first known rationally-defined bacterial consortium in powder form to enter the clinic and has recieved Orphan Drug designation from the US FDA for C. difficile...